Trial Profile
A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Acronyms ASSERT
- Sponsors Centocor; Janssen Biotech
- 13 Jun 2015 Post hoc analysis (syndesmophyte formation) results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 01 Feb 2009 Results published in Annals of the Rheumatic Diseases.
- 01 Apr 2008 Results have been published.